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Intraoperative Radiotherapy (IORT) is a form of accelerated partial breast radiation that has been shown to be equivalent to
conventional whole breast external beam radiotherapy (EBRT) in terms of local cancer control. However, questions have been
raised about the potential of f IORT to produce breast parenchymal changes that could interfere with mammographic surveillance
of cancer recurrence. The purpose of this study was to identify, quantify, and compare the mammographic ﬁndings of patients
who received IORT and EBRT in a prospective, randomized controlled clinical trial of women with early stage invasive breast
cancer undergoing breast conserving therapy between July 2005 and December 2009. Treatment groups were compared with
regard to the 1, 2 and 4-year incidence of 6 post-operative mammographic ﬁndings: architectural distortion, skin thickening, skin
retraction, calciﬁcations, fat necrosis, and mass density. Blinded review of 90 sets of mammograms of 15 IORT and 16 EBRT
patients demonstrated a higher incidence of fat necrosis among IORT recipients at years 1, 2, and 4. However, none of the subjects
were judged to have suspicious mammogram ﬁndings and fat necrosis did not interfere with mammographic interpretation.
1. Background/Context
Recent publication of a randomized trial comparing the ef-
ﬁcacy and safety of targeted intraoperative partial breast ra-
diotherapy (IORT) and standard postoperative whole breast
external bream radiotherapy (WB-EBRT) has drawn world-
wide attention to the promise of IORT for reducing the local
recurrence rate and treatment burden following breast con-
serving surgery [1]. This international, multicenter study of
2233womenwithearly-stageinvasivebreastcancercomeson
the heels of several nonrandomized studies demonstrating
comparable eﬃcacy and safety between standard postoper-
ative WB-EBRT using diﬀerent IORT approaches [2–5]. Col-
lectively, these ﬁndings have laid the foundation for the
emergence of IORT as an alternative to WB-EBRT for the
conservative management of early-stage invasive breast can-
cer.
The current worldwide standard for the management of
invasive and noninvasive breast cancer is mastectomy or
breast-conserving surgery followed by WB-EBRT when local
excision can be achieved with acceptable cosmesis [6–11].
WB-EBRT is commonly prescribed at a total physical radi-
ation dose of 50 Gray (Gy) administered in 25 daily fractions
of 2Gy each, typically followed by 5 daily 2Gy fractions
administered to the tumor bed as a radiation “boost” [12].
IORT is an alternative method of breast radiotherapy in
which a complete course of breast radiotherapy is adminis-
tered at the time of primary tumor resection or reexcision.
IORT administered to the tumor bed may also substitute
for an external beam boost when the patient is expected2 Radiology Research and Practice
to receive WB-EBRT [13, 14]. As a form of accelerated
partialbreastradiotherapy (APBI),thepurpose ofIORTisto
administeracompletecourseofradiotherapy toapredeﬁned
distance beyond the surgical margins in a single fraction of
a p p r o x i m a t e l y2 1G y[ 1]. Not only does this greatly increase
the feasibility and eﬃciency of breast radiotherapy, but also
the targeted irradiation of the index quadrant minimizes
collateral radiation injury to the nonindex quadrants and
more distant tissues (e.g., skin, ribs, lung, heart) through the
use of local shielding, collimators, and skin retractors.
Semiannual or annual diagnostic mammography is rou-
tinely utilized to screen for local recurrence of breast cancer
after breast-conserving surgery. Since the majority of these
recurrences appear within the ﬁrst 5 years postoperatively,
a mammographer’s challenge is to distinguish between the
seminal parenchymal changes associated with cancer recur-
rence and the usual treatment-related changes that may
evolveintheinitialyearsfollowingbreast-conservingtherapy
[10]. The growing popularity of APBI, in general, and
IORT, in particular, has led physicians to question whether
administration of focused, high-dose radiation to the tumor
bed might produce parenchymal changes that could interfere
with mammographic surveillance of cancer recurrence or
leadtoexcessivediagnosticorinvasiveprocedurestoevaluate
mammographic ﬁndings. There are only a few published pa-
pers describing the radiographic appearance of the breast
following IORT [14–18]. With each, investigators observed
varying degrees of fat necrosis and parenchymal scarring,
likely related to the technique of IORT delivery. In this in-
vestigation, we examined the mammographic features of a
subsetofparticipantsinapublishedrandomizedclinicaltrial
comparing WB-EBRT and low-energy IORT delivered using
theIntrabeamSystem(CarlZeissMeditec,Inc.,Oberkochen,
Germany, Figure 1).
2.Design
A retrospective analysis was performed to identify, quantify,
and compare the mammographic ﬁndings among partic-
ipants in the TARGIT Trial, a prospective, randomized,
controlled clinical trial comparing targeted single fraction
IORT to conventional multiple fraction postoperative WB-
EBRT for the treatment of early-stage invasive breast cancer.
The TARGIT trial is a multicenter, international trial of over
2200 participants enrolled at 28 facilities in 9 countries. The
present study is limited to TARGIT Trial participants
enrolled at the University of Southern California Kenneth J.
Norris Comprehensive Cancer Center in Los Angeles, Cali-
fornia. Participants randomized to the WB-EBRT treatment
arm received a 5-week course of daily radiotherapy (45–
50Gy) on stationary linear accelerators at the Kenneth J.
N o r r i sC a n c e rC e n t e ro ra tr a d i a t i o no n c o l o g yc e n t e r si n
their home communities. WB-EBRT recipients also received
a 5-day external beam boost (10Gy) at the discretion of
their treating radiation oncologist. All patients randomized
to the IORT group received IORT to the tumor bed at the
time of initial lumpectomy or at the time of margin
reexcision using the Intrabeam System. The Intrabeam is
(a)
(b)
Figure 1: The Intrabeam System (a) and X-ray source (b).
a low-energy (50kV) radiotherapy system that uses X-
rays to deliver a physical dose of radiation (20Gy) to the
surgical margin using multiple ﬁxed-diameter (Figure 2)o r
expandable applicators to conform the breast tissue around
the X-ray source [19]. Interim 4-year results of the TARGIT
Trial showed statistically equivalent local control and safety
in the IORT and WB-EBRT treatment groups (local rate of
recurrence: 1.2% versus 0.95%, P = 0.41) [1].
All study participants were followed semiannually with
clinical breast examination, diagnostic mammography of the
ipsilateral breast, and annual mammography of the con-
tralateral breast. Mammograms from these followup eval-
uations were selected for review at the 1-, 2-, and 4-year
intervals after surgery. Analysis was limited to participants
with a minimum of 4 years postoperative followup to allow
time for resolution or improvement of acute and subacute
treatment-related parenchymal changes that could aﬀectRadiology Research and Practice 3
Figure 2: Fixed diameter (2–5 centimeter) spherical applicators for
the Intrabeam System.
mammographic interpretation. Mammograms from each
time point were reviewed by a mammographer with more
than 10 years of experience in breast imaging. The mam-
mographer was blinded to the type of breast radiotherapy
received by each study participant. Standard mediolateral
oblique views and craniocaudal views of the aﬀected and
unaﬀectedbreastswereevaluatedforthepresenceof6prede-
ﬁned mammographic features (architectural distortion, skin
thickening, skin retraction, calciﬁcation, fat necrosis, and
mass density) which were assessed, in part, by comparing
each patient’s treated breast to her contralateral untreated
breast. These data points were selected based on published
literature identifying each as a potential sequela of breast
surgery and/breast radiotherapy [20–24]. A BI-RADS score
wasgeneratedusingtheAmericanCollegeofRadiologyanal-
ysis criteria [25]. The following participants were excluded
from this analysis: (1) patients who did not have available
mammograms from each of the speciﬁed time points; (2)
patients who received mastectomy after prior IORT; (3)
patients who were referred for WB-EBRT after prior IORT
due to positive nodes or positive surgical margins. An
analysis of variance with repeated measures was performed
to determine if the incidence of each outcome measure at
years 1, 2, and 4 after surgery was signiﬁcant by treatment
group and across each time point. The study was approved
by the institutional review board.
3. Results
A total of 49 patients were treated in the TARGIT trial
at the University of Southern California Kenneth J. Norris
Comprehensive Cancer Center between April 2005 and
January 2010. Of these patients, 19 were excluded from
centralreviewofimaging:12patientshadnotreached4years
of followup by the time of analysis, 3 patients did not have
mammograms available for central review, and 4 patients
underwent completion mastectomies. The remaining 30
TARGIT trial patients had completed more than 4 years
followup with central review of their surveillance mammo-
grams. 90 sets of mammograms were analyzed for 14 (47%)
patients receiving IORT and 16 (53%) patients receiving
WB-EBRT. The median age of patients participating in the
studywas58years(range40–81).Themediantumorsizewas
15mm (range 3–25) in the IORT cohort and 16mm (range
7–38) in the WB-EBRT cohort (Table 1).
We compared the incidence of each mammographic
ﬁnding in the treatment cohorts using univariate testing
by repeated measures ANOVA. For the between-subjects
measurements, no statistically signiﬁcant diﬀerences were
found in the incidence of architectural distortion (P = 0.21),
skin thickening (P = 0.50), skin retraction (P = 0.39), cal-
ciﬁcations (P = 0.08), or mass density (P = 0.20). However,
the incidence of fat necrosis was observed to be signiﬁcantly
higher in the IORT cohort (P = 0.05) (Table 2(a), Figure 3).
Analysisoftheevolutionofmammographicfeaturesoverthe
4-year period revealed no statistically signiﬁcant temporal
diﬀerences between the two treatment groups for the timing
of feature incidence or resolution. This would indicate that
there were no treatment-based diﬀerences in the appearance
or resolution of architectural distortion, retraction, calciﬁ-
cations, fat necrosis, or mass density over time. However, a
trend of increased skin retraction was observed in the WB-
EBRT group (P = 0.06, Table 2(b)).
Table 3 shows the incidence of six mammographic fea-
tures detected within each arm of the study during the 4-year
followup period. Architectural distortion, skin thickening,
skin retraction, and calciﬁcations were commonly detected
in both arms of the study, with fat necrosis and mass
density occurring less often. Nonetheless, the incidence of
fat necrosis was 3 times higher in the IORT group. In
all cases, areas of fat necrosis acquired a characteristically
benign appearance with the passage of time and with the
formation of macrocalciﬁcations. All of the mammographic
ﬁndings, including the areas of fat necrosis, were judged to
be radiographically benign, and none were given a BI-RADS
categorization of 4 or 5 to indicate the need for a diagnostic
core needle biopsy to rule out recurrent malignancy.
4. Discussion
The growing use of APBI, in general, and IORT, in partic-
ular, has the potential to introduce new challenges in the
mammographic surveillance of breast cancer recurrence. In
one of the ﬁrst studies to address this concern, Sala et al.
compared 45 patients who received IORT (20–24Gy) using
a high-dose rate linear accelerator (Precise Radiotherapy
System, Elekta Oncology, Inc., Stockholm, Sweden) to 45
patients who received WB-EBRT (50Gy + 10Gy boost) and
found that the IORT group demonstrated a greater degree
of architectural distortion, breast edema, and fat necrosis,
each becoming increasingly prominent over the 24 months
period after radiotherapy [15]. Ruch et al. studied 54 patient
who received IORT alone (n = 14, 20Gy) or IORT boost
(n = 40, 20Gy boost followed by 46Gy WB-EBRT) using
the low-energy Intrabeam System and similarly observed a
higher incidence of fat necrosis and prolonged parenchymal
scarring in theIORTboost groupat3yearsoffollowupcom-
pared to a nonrandomized cohort of 48 patients receiving
WB-EBRT alone (55Gy) [18]. In contrast, Kuzmiak et al.
compared 32 IORT patients treated with the high-dose rate4 Radiology Research and Practice
Table 1: Summary of patient age and tumor size.
IORT WB-EBRT Total
Patient total (n)1 4 1 6 3 0
Median age 59 (range 40–73) 57 (range 40–81) 58 (range 40–81)
Median size (mm) 15 (range 3–25) 16 (range 7–38) 15 (range 3–38)
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Figure 3: (a and b): 1-year postoperative bilateral mammograms following IORT showing the development of fat necrosis (circle). (c, d, e):
Mammograms of same patient showing fat necrosis with oil cyst formation at 1 year post-IORT (c), development of a calcifying rim at 2
years post-IORT (d), and resolution of oil cyst with residual calciﬁcations at 4 years post-IORT(e).
Mobetron system (Intraop Medical, Sunnyvale, CA) with
a random sample of 32 patients treated with WB-EBRT
and reported signiﬁcantly more breast edema and surgical
scaring in the WB-EBRT group at 1 year of followup but
did not disclose the incidence of fat necrosis in either group
[16]. Similar to Della Sella and Ruch, Wasser et al. detected
a higher incidence of fat necrosis and parenchymal scarring
following an IORT boost (20Gy followed by 46Gy WB-
EBRT) over a 2-year period compared to a nonrandom
contemporary sample of patients treated with WB-EBRT
with or without an external beam boost (56–66Gy) [14].
In the current investigation, we performed a retrospective
review of mammographic ﬁndings among participants in
the prospective, randomized controlled TARGIT Trial who
received either low-energy-targeted IORT alone (20Gy) or
WB-EBRT with or without an external beam boost (50–
60Gy). Unlike the studies referenced above, we did not
observeastatisticallysigniﬁcantdiﬀerencebetweentheIORT
and WB-EBRT groups in the 1-, 2-, and 4-year incidence of
architectural distortion (i.e., parenchymal scarring). We also
did not detected a statistically signiﬁcant diﬀerence between
the two treatment groups in the 1-, 2-, and 4-year incidence
of dystrophic calciﬁcations, skin retraction, or mass density,
though there was a trend toward a higher incidence of skin
thickening (i.e., breast edema) in the WB-EBRT group as
similarly observed by Kuzmiak. Our most signiﬁcant ﬁnding
was the nearly 3-fold higher incidence of fat necrosis in the
IORT group. This ﬁnding was consistent with the higherRadiology Research and Practice 5
Table 2: Summary of statistical analysis using univariate ANOVA
with repeated measures.
(a)
Treatment
× ﬁnding
WB-EBRT
(n = 16)
IORT
(n = 14) FP -value
Architectural distortion
Year 1 9 9
Year 2 6 9
Year 4 5 8
Total 20 26 1.65 0.21
Skin thickening
Year 1 8 4
Year 2 7 5
Year 4 7 6
Total 22 15 0.47 0.5
Retraction
Year 1 4 9
Year 2 8 7
Year 4 8 7
Total 20 23 0.76 0.39
Calciﬁcations
Year 1 0 1
Year 2 2 6
Year 4 3 5
Total 5 12 3.24 0.08
Fat necrosis
Year 1 0 3
Year 2 2 5
Year 4 1 5
Total 3 13 4.2 0.05
Mass density
Year 1 1 1
Year 2 3 0
Year 4 0 0
Total 41 1 . 7 0 . 2
(b)
Treatment × time FP -value
Architectural distortion 0.87 0.43
Skin thickening 0.58 0.56
Retraction 3.01 0.06
Calciﬁcations 1.06 0.36
Fat necrosis 0.32 0.73
Mass density 1.72 0.19
incidence of IORT-related fat necrosis reported by Sala,
Wasser, and Ruch. In contrast with Ruch et al., fat necrosis
did not confound the interpretation of the mammograms
in the IORT group and none of the subjects were given
a BI-RADS score of 4 or 5 to indicate the presence of
a mammographic ﬁnding warranting a diagnostic core
needle biopsy.
Fat necrosis following breast surgery or breast radiother-
apy results from tissue devitalization leads to liquefactive
necrosis, formation of oil cysts (liqueﬁed fat) or ﬁbrous
scars, and frequent aggregation of spherical lucent centered
macrocalciﬁcations or “eggshell” calciﬁcations surrounding
an oil cyst. In addition to the present study, three out of four
ofthereferencedstudiesrecognizedfatnecrosisasacommon
ﬁnding in patients treated with either IORT alone or IORT
administered as a boost, with increased fat necrosis being
observed after high- and low-energy treatments. While it is
reasonable to attribute the higher incidence of fat necrosis
after IORT to the delivery of a focal dose of radiation to the
tumor bed, a number of other factors may contribute to the
posttreatment artifacts observed in IORT-treated patients.
Foremost among these are the surgical methods and IORT
techniques used to prepare the breast for IORT which
typically involves circumferential dissection of the skin edges
away from the underlying breast parenchyma, placement of
conforming sutures to stabilize the surgical margins during
the radiotherapy treatment, and possible dissection of the
breast parenchyma oﬀ the chest wall to create a space
for placement of a radiation barrier. Use of a radiation
barrier is mandatory when the high-dose rate systems are
used (e.g., Mobetron or Novac7) but optional with the
Intrabeam due to rapid attenuation of the low-energy dose
by normal tissues. In the treatment period covered in this
investigation, the surgeon routinely used circumferential
skin ﬂap dissection, conforming suture placement, and
radiation barrier placement to prepare the breast for IORT,
and any of these steps could have contributed to the higher
incidence of fat necrosis observed in the IORT cohort.
In more recent years, we have limited the extent of skin
dissection to minimize the risk of fat necrosis, and radiation
b a r r i e r sa r en o wu s e dm o r es e l e c t i v e l yb a s e do nr e c e n td a t a
conﬁrmingmarkeddoseattenuation.Radiographicfollowup
of more recently treated patients will determine how these
technique modiﬁcations inﬂuence mammographic ﬁndings
in IORT-treated patients. The reference articles did not
provide suﬃcient data to determine how IORT administered
alone or as a boost impacts the incidence of fat necrosis.
Postoperative mammographic ﬁndings after IORT might
also be inﬂuenced by the techniques used by surgeons to
close the surgical cavity after breast surgery. Partial thickness
closure of the lumpectomy cavity might have contributed
to the higher incidence of persistent hematoma/seromas or
oils cysts observed in the referenced studies, whereas full-
thickness closure of the surgical cavity among IORT and
WB-EBRT recipients likely contributed to a lower incidence
of persistent seroma in the present study. Interestingly,
a signiﬁcantly higher incidence of recurrent seromas was
reported among IORT recipients in the TARGIT Trial (IORT
2.1% versus WB-EBRT 0.8%, P = 0.012). However, the
trial did not document the manner of wound closure nor
did it track posttreatment mammogram ﬁndings to allow
assessment of the long-term impact of wound closure tech-
niques. Asymptomatic and symptomatic seroma formation
is a commonly reported sequela of intracavity brachytherapy6 Radiology Research and Practice
Table 3: Number and percentage of patients presenting with each mammographic ﬁnding in at least one screening mammogram.
Mammographic ﬁnding IORT (n = 14) WBEBRT (n = 16) Total (n = 30)
Architectural distortion 8 57.1% 9 56.2% 17 56.7%
Skin thickening 7 50.0% 10 62.5% 17 56.7%
Retraction 6 42.9% 10 62.5% 16 53.3%
Calciﬁcation 6 42.9% 4 25.0% 10 33.3%
Fat necrosis 5 35.7% 2 12.5% 7 23.3%
Mass density 1 7.1% 4 25.0% 5 16.6%
(e.g., MammoSite), the most widely used form of breast
APBI, but seroma formation does not appear to signiﬁcantly
impair the radiographic surveillance of cancer [26].
There are several important limitations of the present
study. Unlike the Della Sella and Wasser studies which
reviewed multiple imaging modalities, we only examined
the mammographic features of breasts treated with IORT
or WB-EBRT. Had we expanded our assessment to include
breast ultrasound or breast magnetic resonance imaging,
we may have observed additional ﬁndings that could have
aﬀected our interpretation of the impact of IORT on mam-
mography. However, since neither ultrasound nor MRI were
routinely performed during the postoperative surveillance
of study participants, we are unable to characterize the
sonographic or MRI manifestations of breast IORT.
Another limitation of our study is the relatively small
sample size of 30 patients. Since we limited the retrospective
review to only those patients with a minimum of 4 years
postoperative followup, the number of patients in our study
was smaller. Despite these limitations, our study has several
key strengths that make it an important contribution to
the body of literature on postradiotherapy breast cancer
surveillance following APBI. First, this 4-year radiographic
followup of study participants provides the most long-term
imagingevaluationinvolvinganyformofIORTofthebreast.
Restrictingthestudytopatientswith4-yearfollowupallowed
us to analyze the temporal inﬂuence of surgery and breast
radiotherapy on mammographic interpretation. Although
the incidence of symptomatic seromas requiring aspiration
might in theory be higher in the immediate postoperative
period among IORT recipients, the fact that none of
our patients exhibited suspicious mammographic ﬁndings
provides reassurance that low-energy IORT is unlikely to
increase the need for invasive diagnostic biopsies to rule
out recurrent malignancy. Another important strength of
this study was our ability to limit selection and treatment
bias among study participants. Selection bias was limited
by restricting the analysis to participants in a prospective,
randomized clinical trial and treatment bias was minimized
by the fact that both cohorts were treated by a single surgeon
who routinely performed full-thickness oncoplastic wound
closure following tumor resection.
An additional strength of the present study was the in-
vestigator’s use of an image assessment scorecard to evaluate
the presence, extent, or absence of 6 distinct mammographic
ﬁndings, using each patient’s contralateral breast as an
internal control. Although not all patients obtained followup
mammograms at USC where digital mammograms are
routinely performed, mammographic interpretation was
facilitated by scanning all analog ﬁlms to digital media prior
to interpretation. Observer bias was minimized by having all
mammograms retrospectively reviewed by a blinded central
mammographer instead of using interpretations provided by
other mammographers who might have been aware of the
radiotherapy treatment received.
All studies were originally read as BIRADS 2 or 3, and
the retrospective review performed as part of this study con-
ﬁrmed those interpretations. The study radiologist was not
necessarily the same radiologist who performed the original
interpretation. While this does not quite constitute a double-
reading, the factthat none of the study subjectswere assessed
to have BIRADS 4 or 5 mammograms (either originally or
retrospectively) underscores the most important ﬁnding in
this study that IORT did not increase the need for diagnostic
core needle biopsies.
5. Conclusion
IORT is a form of APBI that has been shown to be equivalent
to conventional WB-EBRT in terms of local cancer control
and safety. In this blinded review of 90 sets of mammograms
from 14 IORT and 16 WB-EBRT patients, we found a
signiﬁcant increase in the incidence of fat necrosis in the
IORT cohort compared to patients treated with WB-EBRT.
However, none of the study participants were observed to
have suspicious mammographic ﬁndings. Based on these
ﬁndings, we conclude that IORT and WB-EBRT have an
almost equivalent potential to aﬀect mammographic inter-
pretation and that IORT does not disproportionately impair
mammographic surveillance for breast cancer recurrence.
Further studies will be needed to determine how limiting
the extent of skin and parenchymal dissection inﬂuences the
incidence fat necrosis after IORT.
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